# Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

> **NCT05642208** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Nantes University Hospital** · enrollment: 256 (estimated)

## Conditions studied

- Atopic Dermatitis
- Eczema, Atopic

## Interventions

- **DRUG:** Dupilumab step-down

## Key facts

- **NCT ID:** NCT05642208
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-08
- **Primary completion:** 2026-09-08
- **Final completion:** 2026-09-08
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05642208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05642208, "Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05642208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*